Mapmygenome Completes Acquisition of dnaPower Inc. to Accelerate North American Expansion in DNA, Microbiome, Longevity and Precision Health Testing
PR Newswire
VANCOUVER, BC, Oct. 21, 2026
VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ — Mapmygenome announced the completion of its acquisition of Vancouver-based dnaPower Inc., a pioneer in personal genomics. The strategic transaction expands Mapmygenome’s North American footprint and establishes a market-leading platform in DNA testing, gut microbiome health, longevity, and AI-driven multi-omics testing
By uniting dnaPower with Mapmygenome’s global scale and premier CAP-accredited clinical laboratory capabilities, including Vancouver-based Microbiome Insights, acquired in 2025, the acquisition creates a centralized platform for DNA, microbiome, pharmacogenetic, and longevity testing dedicated to proactive, preventive healthcare across Canada and the US
“Acquiring dnaPower is a pivotal step in scaling our North American operations,” said Anu Acharya, Founder and CEO of Mapmygenome. “Pairing dnaPower’s commercial trajectory with our CAP-accredited clinical laboratories and AI capabilities positions us to define the next frontier in microbiome, longevity, and precision health testing.”
“Joining Mapmygenome unlocks an extraordinary growth chapter for dnaPower,” said Dr. Lois Nahirney, Founder and CEO of dnaPower. “Backing from a global leader with elite laboratory infrastructure gives us the foundation to scale rapidly across North America, delivering advanced, high-quality products directly to our clients.”
Strategic Highlights
- Market Expansion: Integrates dnaPower’s consumer reach with Mapmygenome’s global footprint, technology stack, and R&D pipeline.
- Integrated Longevity Engine: Combines multi-omics analytics and clinical laboratory capabilities to deploy new commercial offerings in healthy aging, gut profiling, and epigenetic assessment.
- Centralized Operations: Establishes a Vancouver processing hub operating under CAP-accredited and ISO-certified protocols.
Comprehensive Testing Suite
- Longevity and Gut Health: Advanced shotgun metagenomic sequencing, gut microbiome profiling, epigenetic biological age panels, and longevity insights.
- Genomic and Preventive Health: Whole-genome and exome sequencing, pharmacogenetics, DNA wellness panels, methylation testing, and clinical bioinformatics.
About Mapmygenome
Mapmygenome is a global leader in personal genomics, longevity solutions, and precision medicine. Combining AI-driven multi-omics with premier CAP-accredited clinical laboratory infrastructure, Mapmygenome empowers individuals and healthcare providers with actionable insights across whole-genome sequencing, gut health, and healthy aging to transform preventive care worldwide
Learn more: mapmygenome.ai
About dnaPower
Founded in 2008 and based in Vancouver, dnaPower specializes in actionable DNA-based health, nutrition, fitness, methylation, and longevity insights for consumers and practitioners
Learn more: dnaPower.com
About Microbiome Insights
Microbiome Insights, a Mapmygenome company, is a Canadian provider of CAP-accredited DNA, microbiome, and multi-omics sequencing, analytics, and bioinformatics services
Learn more: Microbiomeinsights.com
Media ContactEmail:anu@mapmygenome.ai
View original content to download multimedia:https://www.prnewswire.com/news-releases/mapmygenome-completes-acquisition-of-dnapower-inc-to-accelerate-north-american-expansion-in-dna-microbiome-longevity-and-precision-health-testing-302915388.html
SOURCE Mapmygenome
The articles, information, and content displayed on this webpage may
include materials prepared and provided by third parties. Such
third-party content is offered for informational purposes only and
is not endorsed, reviewed, or verified by Morningstar
Morningstar makes no representations or warranties regarding the
accuracy, completeness, timeliness, or reliability of any third-party
content displayed on this site. The views and opinions expressed in
third-party content are those of the respective authors and do not
necessarily reflect the views of Morningstar, its affiliates, or employees
Morningstar is not responsible for any errors, omissions, or delays
in this content, nor for any actions taken in reliance thereon.
Users are advised to exercise their own judgment and seek independent
financial advice before making any decisions based on such content.
The third-party providers of this content are not affiliated with
Morningstar, and their inclusion on this site does not imply any
form of partnership, agency, or endorsement.
Plus, a deep dive on SpaceX’s bid to challenge US telecoms.
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing.
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026.
A difficult problem has an easy solution.
The stocks of these high-quality companies look cheap today.
